Alemtuzumab shows strong results in 10 year follow-up

Written by Alice Weatherston

Research to be presented today at the American Academy of Neurology (AAN) 68th Annual Meeting (Vancouver, BC, Canada, 15–21 April 2016) will reveal a long-term analysis detailing 10 years of clinical efficacy of alemtuzumab (Lemtrada®) in patients with relapsing-remitting multiple sclerosis (RRMS). The presentation discusses the results of the ongoing, long-term extension study of the Phase 2 CAMMS223 trial which recruited individuals with RRMS who had not previously been treated for the disease. Alemtuzumab is a humanized monoclonal antibody therapy, selectively targeting the protein CD52 on B and T cells. Treatment results in a reduction in the numbers of circulating...

To view the full article, please register now for access

It's completely free